AgonOx, Inc. logo — DISCOVERING AND DEVELOPING NEW IMMUNOTHERAPY AGENTS TO IMPRO...

AgonOx, Inc.

DISCOVERING AND DEVELOPING NEW IMMUNOTHERAPY AGENTS TO IMPROVE THE LIVES OF THOSE LIVING WITH CANCER.

Founded 2012 5 employees Biotechnology, Pharmaceutical

General Information

Company Name AgonOx, Inc.
Founded Year 2012
Employees 5
Industries Biotechnology, Pharmaceutical
Social

Get notified when AgonOx, Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About AgonOx, Inc.

AgonOx, Inc. is a biotechnology and pharmaceutical company founded in 2012. The company's primary focus is on discovering and developing new immunotherapy agents to improve the lives of those living with cancer. Through its research strategy which revolves around the interaction between T cells and tumor cells, AgonOx aims to develop novel therapies to treat cancer patients. The company utilizes bioinformatics, in-vitro, and in-vivo testing to identify and validate new therapeutic approaches. A significant aspect of AgonOx's operations is its collaboration with the Portland Providence Cancer Center, where staff scientists closely work with oncologists, surgeons, and immunologists. This collaboration has resulted in two first-in-human clinical trials, with the latest trial commencing in August 2023. In recent years, the company has placed particular emphasis on the utilization of selected tumor-reactive T cells in adoptive cell therapy for the treatment of patients with solid malignancies. While the specific details about the headquarters location and the last investment remain undisclosed, the company's progress in developing innovative cancer therapies positions it as an intriguing opportunity for potential investors in the biotechnology and pharmaceutical industries.

Taxonomy: Cancer immunotherapy, Immunology, Drug discovery, Oncology, Cancer research, T cell-based immunotherapy, Combination treatments, Immune phenotyping, Bioinformatics, In-vitro testing, In-vivo testing, Clinical trials, Immune-specific pathways, Recombinant proteins, Antibody development

No funding data available for AgonOx, Inc. yet.

Get notified when AgonOx, Inc. raises funding

AgonOx, Inc. Alternatives & Competitors

AgonOx, Inc. vs

Pioneering immune-based therapies to harness the body's defenses against cancer through advanced imm...

Grant
11 employees
Biotechnology, Health Care
AgonOx, Inc. vs
Immunowake, Inc.
Immunowake, Inc. United States

Immunowake Inc. is a private, pre-clinical stage biotechnology company focused on cancer drug discov...

Series A
2 employees
Biotechnology
AgonOx, Inc. vs

Biond - Innovative immunotherapies and a pioneering intracellular delivery for biologics for the tre...

Series C
43 employees
Biotechnology, Health Care

FAQ About AgonOx, Inc.

DISCOVERING AND DEVELOPING NEW IMMUNOTHERAPY AGENTS TO IMPROVE THE LIVES OF THOSE LIVING WITH CANCER.
AgonOx, Inc. was founded in 2012.
AgonOx, Inc. operates in the following industries: Biotechnology, Pharmaceutical.
AgonOx, Inc. has approximately 5 employees.
Top alternatives and competitors to AgonOx, Inc. include ImmunoCellular Therapeutics Ltd, Immunowake, Inc., Biond Biologics Ltd, Surface Oncology Inc., Thunder Biotech. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AgonOx, Inc. and ImmunoCellular Therapeutics Ltd are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors AgonOx, Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy